Holen Sie sich die Stockscreener-App
13.00
6.20%
-0.86
Handel nachbörslich:
12.95
-0.05
-0.38%
Contineum Therapeutics Inc Aktie (CTNM) Neueste Nachrichten
Contineum Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Business Wire
6,083,338 Class B common stock of Contineum Therapeutics, Inc. are subject to a Lock-Up Agreement Ending on 12-MAR-2026. - marketscreener.com
Update Recap: How sensitive is Contineum Therapeutics Inc to inflationQuarterly Profit Review & Daily Chart Pattern Signals - baoquankhu1.vn
Contineum Therapeutics, Inc. (CTNM) Upgraded to Buy: What Does It Mean for the Stock? - MSN
Can Contineum Therapeutics Inc. stock resist sector downturns2026 Institutional & Risk Adjusted Buy and Sell Alerts - Naître et grandir
Contineum Therapeutics (NASDAQ:CTNM) Lowered to "Sell" Rating by Wall Street Zen - MarketBeat
Analysts Offer Insights on Healthcare Companies: GH Research (GHRS) and Sionna Therapeutics, Inc. (SION) - The Globe and Mail
Contineum Therapeutics (NASDAQ:CTNM) Price Target Raised to $20.00 at Robert W. Baird - MarketBeat
Contineum Therapeutics Expands ATM Facility, Highlights Pipeline Progress - The Globe and Mail
Stifel reiterates Buy on Contineum stock, keeps $29 price target By Investing.com - Investing.com South Africa
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Developme - PharmiWeb.com
Stifel reiterates Buy on Contineum stock, keeps $29 price target - Investing.com India
Contineum Therapeutics Reports Fourth-Quarter 2025 Financial Results; Affirms Key Clinical Development Milestones - The National Law Review
Contineum Therapeutics (NASDAQ:CTNM) Posts Earnings Results, Beats Expectations By $0.01 EPS - MarketBeat
Contineum reports Q4 EPS (49c), consensus (39c) - TipRanks
Contineum Therapeutics Q4 Earnings Summary & Key Takeaways - Benzinga
CTNM: Phase 2 IPF trial dosing started, $93M raised, and cash runway extends into mid-2029 - TradingView
Contineum Therapeutics (NASDAQ: CTNM) posts Q4 loss, adds $100,000,000 at-the-market stock capacity - Stock Titan
According to the latest public documents from the U.S. Securities and Exchange Commission (SEC), biopharmaceutical company Contineum Therapeutics Inc. has launched a new stock offering plan. - Bitget
CTNM SEC FilingsContineum Therapeutics 10-K, 10-Q, 8-K Forms - Stock Titan
USD News Center - University of San Diego
Contineum Therapeutics to Present at the 2026 Leerink Partners Global Healthcare Conference - Business Wire
CTNMContineum Therapeutics Latest Stock News & Market Updates - Stock Titan
Contineum Therapeutics to Present at September Investor Conferences - Business Wire
Lorrain Daniel S. sells Contineum Therapeutics (CTNM) shares By Investing.com - Investing.com Australia
Contineum Therapeutics (CTNM) CMO sells $54,220 in stock - Investing.com
Lorrain Daniel S. sells Contineum Therapeutics (CTNM) shares - Investing.com
Contineum Therapeutics (CTNM) CMO sells $54,220 in stock By Investing.com - Investing.com UK
Contineum Therapeutics (CTNM) CSO sells shares under 10b5-1 plan - Stock Titan
Contineum Therapeutics (CTNM) CMO sells 3,611 shares via 10b5-1 - Stock Titan
Beat the Market with Zacks: Spotlight on Contineum Therapeutics, Suzano, and PepsiCo - Bitget
Beat the Market the Zacks Way: Contineum Therapeutics, Suzano, PepsiCo in Focus - Yahoo Finance
Earnings Beat: Is Contineum Therapeutics Inc gaining market shareJuly 2025 Momentum & Free Technical Pattern Based Buy Signals - baoquankhu1.vn
Contineum Therapeutics CSO Lorrain S. Daniel sells $130k in CTNM stock - Investing.com Nigeria
Contineum Therapeutics (CTNM) CEO sells 7,100 shares, exercises options - Stock Titan
Contineum Therapeutics (CTNM) CSO exercises options and sells 8,124 shares - Stock Titan
Contineum Therapeutics (CTNM) Projected to Post Earnings on Thursday - MarketBeat
CTNM Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Is Contineum Therapeutics Inc gaining market shareEarnings Summary Report & AI Driven Stock Price Forecasts - baoquankhu1.vn
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
Contineum Therapeutics, Inc. (NASDAQ:CTNM) Given Average Rating of “Moderate Buy” by Analysts - Defense World
CTNM Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Balyasny Asset Management L.P. Increases Stake in Contineum Ther - GuruFocus
Balyasny Asset Management L.P. Increases Stake in Contineum Therapeutics Inc. - GuruFocus
What’s the MACD signal for Contineum Therapeutics Inc.July 2025 Snapshot & Daily Volume Surge Signals - mfd.ru
A | Can IRDM navigate macro headwindsJuly 2025 Movers & Consistent Return Strategy Ideas - mfd.ru
Contineum (NASDAQ: CTNM) CSO trades shares under 10b5-1 plan - Stock Titan
Will Contineum Therapeutics Inc. stock continue dividend increasesJuly 2025 Opening Moves & Verified Momentum Stock Ideas - mfd.ru
RA Capital discloses 7.2% Contineum Therapeutics (CTNM) ownership stake - Stock Titan
Balyasny discloses 7.6% Contineum (CTNM) stake via ADMF fund - Stock Titan
Published on: 2026-02-15 23:21:35 - mfd.ru
Can Contineum Therapeutics Inc. stock outperform in a bear marketTrade Exit Summary & Entry Point Strategy Guides - mfd.ru
0.48%
1.21%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):